

Novartis US COVID-19 Initiatives

Novartis US Foundation Provides Support to 40 Community Organizations for COVID-19 Pandemic Response Efforts

Since launching the COVID-19 Community Response Fund on April 3, 2020, Novartis and the Novartis US Foundation have donated \$5M to help US communities keep their residents healthy during the COVID-19 pandemic. [Click here](#) to read more.

Ensuring Patient Access During COVID-19

During these uncertain and uniquely challenging times, we know that many people are facing hardships resulting from job loss, illness, or strained access to healthcare services. We stand ready to support those in need by providing relief through our many patient support programs.

We believe that our commitment to ensuring access to our medicines has never been more important. In the last five years, approximately 299,000 patients received free medication valued at over USD 7.9 billion through the Novartis Patient Assistance Foundation Inc. And, in 2019, approximately 520,500 patients received copay assistance.

Now, we are building on this legacy by enhancing our offerings to help those experiencing difficulties resulting from the COVID-19 crisis. This includes simpler access to free medicines for eligible patients and expanded programs to improve affordability and patient support. We will continue to monitor and expand our services where possible to ensure patients have access to the support they need during this challenging time.

Patient Assistance

Through our [Patient Assistance](#), we help all patients find programs that may provide savings or resources, as well as access to their Novartis prescriptions medications. The website is easy to navigate; patients just answer a few questions to find out what programs they qualify for.

The Novartis Patient Assistance Foundation, Inc. (NPAF)

Patients experiencing financial hardship and have limited or no prescription coverage may be eligible to receive Novartis medications for free. This includes those who may be experiencing a sudden job loss or loss of insurance due to COVID-19. We have simplified the application process to ensure patients get the medicines they need easily and quickly. [Click here](#) or call 1 800 277 2254 for more information NPAF.

Patient Support Programs for Each Novartis Medication

In light of COVID-19, Novartis is implementing flexible therapeutic access and support, wherever possible, for some of our most widely-used medicines through our patient support programs for each of our medications. For example, this may include free temporary supplies of certain medications to avoid treatment gaps, expanded in-home onboarding and administration support, extended fill co-pay card support, and where available, extended refills for free-drug programs. Contact 1-888-NOW-NOVA or visit the specific Novartis medication website for information on how to enroll.

We have also ramped up our services to help answer patients' general and therapy-specific COVID-19 questions – and leveraging our Patient & Specialty Services team to perform virtual outreaches to patients, as appropriate, to lend support.

Contact Us

We are here to answer patient questions and can be reached at 1-888-NOW-NOVA (1 888 669 6682) Monday - Friday, 8:30 AM - 5:00 PM ET. In case of Medical Emergency, please contact your physician immediately.

Novartis donation

Contributions upwards of USD 40 million to over 60 projects around the world that support local communities impacted by this crisis. These include major donations to strengthen medical infrastructure and provide on-site support in many countries.

Commitment to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response. Sandoz, the Novartis generics and biosimilars division, is also maintaining prices on a basket of essential medicines that may help in the treatment of COVID-19.

External collaborations

We are undertaking several efforts to leverage our capabilities in discovery, development and scale-up manufacturing. We are partnering with multi-stakeholder external consortia, including:

- COVID-19 Therapeutics Accelerator, coordinated by the Bill & Melinda Gates Foundation, Wellcome Trust and MasterCard
 - COVID-19 direct partnership organized by Innovative Medicines Initiative
 - ACTIV partnership planned by National Institutes of Health
 - Member of R&D Leaders Consortium
 - Drug discovery efforts with the University of California, Berkeley
-

Finding New Ways Forward

"Thanks to you, we're finding new ways forward."

COVID-19 has profoundly impacted the US, and we want to express our deep gratitude to those on the front lines who are helping communities across the country. This campaign recognizes the courage and care being shown by front-line workers, who are inspiring us to continue to work toward a better tomorrow. We are committed to doing all we can to support those during this time of need.

Source URL: <https://qa1.novartis.us/coronavirus/novartis-us-covid-19-initiatives>

List of links present in page

1. <https://qa1.novartis.us/coronavirus/novartis-us-covid-19-initiatives>
2. <https://qa1.novartis.us/coronavirus/novartis-us-covid-19-initiatives/novartis-us-foundation-provides-support-40-community-organizations-covid-19-pandemic-response-efforts>
3. <https://qa1.novartis.us/patients-and-caregivers/patient-assistance>
4. <https://qa1.novartis.us/patients-and-caregivers/patient-assistance/patient-assistance-foundation->

enrollment